SBRT plus immunotherapy for small liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of hepatocellular carcinoma (a type of liver cancer).
- Your liver cancer lesions must be small (total diameter up to 5 cm) and no more than 2 tumors, without spread to blood vessels or other organs.
- You should not have been treated with immune checkpoint inhibitors before.
- You must be between 18 and 75 years old.
- Your liver function must be well preserved (Child-Pugh class A, meaning mild cirrhosis).
- You must not have active hepatitis B or C infection with high viral levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
This trial is testing whether giving focused radiation therapy (SBRT) after liver surgery helps lower the chance of cancer coming back. It is for people whose surgery left a very small safety margin around the tumor.
This early-phase trial tests a treatment plan that combines focused radiation with two medicines—an immunotherapy drug and an anti-angiogenesis drug—to treat hepatocellular carcinoma (liver cancer). It may help shrink tumors or control disease when surgery or ablation can’t be used, and when systemic (whole-body) treatment is needed.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) for liver cancer that can be removed with surgery. The goal is to see if this combination can shrink tumors before surgery and help prevent the cancer from coming back.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial tests whether a targeted radiation therapy (SBRT) can help people with liver cancer whose disease has only a few new spots growing while on first-line immunotherapy. It aims to see if zapping those spots can control the cancer and delay the need for stronger treatments.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.